Emergent BioSolutions (STU:ER4) Tariff Resilience Score: 7/10 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:ER4 Emergent BioSolutions Inc STU:ER4
61 GF Score
Price €6.58
GF Value €4.16
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Emergent BioSolutions Tariff Resilience Score?

Emergent BioSolutions STU:ER4 -6.67% 61 Tariff Resilience Score is 7 as of Jul. 15, 2026. GuruFocus rates STU:ER4 with a GF Score™ of 61/100 and a GF Value™ of €4.16 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,029 Drug Manufacturers companies, Emergent BioSolutions ranks better than 97.08% on this metric.

Emergent BioSolutions has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Emergent BioSolutions has Emergent BioSolutions has moderate exposure to tariffs due to its global supply chain for pharmaceutical ingredients. However, its critical role in public health and government contracts offer some insulation.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Emergent BioSolutions might have Highly Resilient.

Emergent BioSolutions  (STU:ER4) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Emergent BioSolutions Tariff Resilience Score Related Terms

STU:ER4 vs ELTP, NIKA, EOLS: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emergent BioSolutions Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's Tariff Resilience Score falls into.


STU:ER4
61GF Score
Emergent BioSolutions Inc STU:ER4
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Emergent BioSolutions (STU:ER4) has a Tariff Resilience Score of 7 as of Jul. 15, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Emergent BioSolutions ranks #30 out of 1029 companies in the Drug Manufacturers industry, placing it in the top 2.9%.
Is Emergent BioSolutions' Tariff Resilience Score too high?
Emergent BioSolutions' current Tariff Resilience Score is 7. Based on the distribution chart, Emergent BioSolutions ranks #30 out of 1029 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Emergent BioSolutions has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Emergent BioSolutions' Tariff Resilience Score compare to ELTP and NIKA?
According to the Drug Manufacturers industry distribution chart, Emergent BioSolutions ranks #30 out of 1029 companies for Tariff Resilience Score. This places Emergent BioSolutions in the top 3% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Emergent BioSolutions's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emergent BioSolutions stock overvalued right now?
Based on GuruFocus' analysis, Emergent BioSolutions (STU:ER4) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.16, compared to a current price of €6.58 — trading 58.1% above its estimated fair value. The current Tariff Resilience Score is 7. Emergent BioSolutions' overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Emergent BioSolutions (STU:ER4), the current Tariff Resilience Score is 7 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Emergent BioSolutions (STU:ER4) Overvalued in 2026?

Based on GuruFocus' analysis, Emergent BioSolutions stock appears to be overvalued. The current stock price of €6.58 is trading 58.1% above its estimated GF Value™ of €4.16. GuruFocus considers Emergent BioSolutions to be Significantly Overvalued.

Key valuation signals for STU:ER4:

  • Tariff Resilience Score: 7
  • GF Value™: €4.16 vs. price of €6.58 (58.1% above fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the STU:ER4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Emergent BioSolutions Business Description

Other Exchanges EBS:USA0IGA:UK
Address 300 Professional Drive, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
61GF Score

Get the complete analysis for STU:ER4

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.58
Price
€4.16
GF Value